<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
Certification and Notice of Termination of Registration under Section 12(g) of
the Securities Exchange Act of 1934 or Suspension of Duty to File Reports
under Sections 13 and 15(d) of the Securities Exchange Act of 1934.
Commission File Number: 0-20138
PHARMAGENICS, INC.
(Exact name of registrant as specified in its charter)
FOUR PEARL COURT, ALLENDALE, NEW JERSEY 07401
(201) 818-1000
(Address, including zip code, and telephone number, including area code,
of registrant's principal executive offices)
SERIES B CONVERTIBLE PREFERRED STOCK, $0.01 PAR VALUE
WARRANTS TO PURCHASE SHARES OF COMMON STOCK, $0.01 PAR VALUE
(Title of each class of securities covered by this Form)
NONE
(Titles of all other classes of securities for which a duty to file reports
under Section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1)(i) [X] Rule 12h-3(b)(1)(ii) [ ]
Rule 12g-4(a)(1)(ii) [ ] Rule 12h-3(b)(2)(i) [ ]
Rule 12g-4(a)(2)(i) [ ] Rule 12h-3(b)(2)(i) [ ]
Rule 12g-4(a)(2)(ii) [ ] Rule 12h-3(b)(2)(ii) [ ]
Rule 12h-3(b)(1)(i) [ ] Rule 15d-6 [ ]
Approximate number of holders of record as of the certification or notice
date: NONE
Pursuant to the requirements of the Securities Exchange Act of 1934 GENZYME
CORPORATION, as successor to PHARMAGENICS, INC. by merger, has caused this
certification/notice to be signed on its behalf by the undersigned duly
authorized person.
Date: June 18, 1997 GENZYME CORPORATION
By: /s/ Peter Wirth
------------------------------------
Peter Wirth
Executive Vice President and Chief
Legal Officer
